2 16

Cited 0 times in

Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults

Authors
Ku, CR; Brue, T; Schilbach, K; Ignatenko, S; Magony, S; Chung, YS; Kim, BJ; Hur, KY; Kang, HC; Kim, JH; Kim, MS; Kowalska, A; Bolanowski, M; Ruchala, M; Damjanovic, S; Payer, J; Choi, YJ; Heo, SJ; Kim, TK; Heo, M; Lee, J; Lee, EJ
Citation
European journal of endocrinology, 179(3):169-179, 2018
Journal Title
European journal of endocrinology
ISSN
0804-46431479-683X
Abstract
OBJECTIVE: Hybrid Fc-fused rhGH (GX-H9) is a long-acting recombinant human growth hormone (GH) under clinical development for both adults and children with GH deficiency (GHD). We compared the safety, pharmacokinetics and pharmacodynamics of weekly and every other week (EOW) dosages of GX-H9 with those of daily GH administration in adult GHD (AGHD) patients.
DESIGN: This was a randomized, open-label, active-controlled and dose-escalation study conducted in 16 endocrinology centers in Europe and Korea.
METHODS: Forty-five AGHD patients with or without prior GH treatment were enrolled. Patients with prior GH treatments were required to have received the last GH administration at least 1 month prior to randomization. Subjects were sequentially assigned to treatment groups. Fifteen subjects were enrolled to each treatment group and randomly assigned to receive either GX-H9 or Genotropin (4:1 ratio). GX-H9 dosage regimens for Groups 1, 2 and 3 were 0.1 mg/kg weekly, 0.3 mg/kg EOW and 0.2 mg/kg EOW, respectively. All Genotropin-assigned subjects received 6 microg/kg Genotropin, regardless of treatment group. Main outcome analyses included measurements of serum insulin-like growth factor 1 (IGF-I), safety, pharmacokinetics, pharmacodynamics and immunogenicity.
RESULTS: Mean GX-H9 peak and total exposure increased with an increase in dose after a single-dose administration. The mean IGF-I response was sustained above baseline over the intended dose interval of 168 h for the weekly and 336 h for the EOW GX-H9 groups. Safety profiles and immunogenicity were not different across the treatment groups and with Genotropin.
CONCLUSIONS: GX-H9 has the potential for up to twice-monthly administration.
MeSH terms
AdultFemaleHuman Growth Hormone/administration & dosage*Human Growth Hormone/deficiency*HumansImmunoglobulin DImmunoglobulin Fc FragmentsImmunoglobulin GInsulin-Like Growth Factor I/analysisMaleMiddle AgedRecombinant Fusion Proteins/administration & dosage*Treatment Outcome
DOI
10.1530/EJE-18-0185
PMID
29973375
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
AJOU Authors
정, 윤석
Files in This Item:
Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse